# An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor

> **NCT00441610** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Gimatecan

## Key facts

- **NCT ID:** NCT00441610
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-09
- **Final completion:** —
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441610, "An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00441610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*